display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced UC (mUC) - 1st Line (L1)
mUC - L1 - all population
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-361 ...
pembrolizumab plus SoC KEYNOTE-361 ...

Study type: